Sign In
Buy FENC
$9.14
-0.84 (-8.42%)
At Close: Jun 03, 2026
Recent Price Trend in Adherex Technologies (FENC) is Your Friend, Here's Why
09:50am, Tuesday, 15'th Jul 2025
Adherex Technologies (FENC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it
Fennec Announces Results of Annual Meeting
04:31pm, Tuesday, 03'rd Jun 2025
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy
Fennec Pharmaceuticals Inc. (FENC) Q1 2025 Earnings Call Transcript
12:23pm, Tuesday, 13'th May 2025
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer
Adherex Technologies Inc. (FENC) Reports Q1 Loss, Tops Revenue Estimates
08:15am, Tuesday, 13'th May 2025
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.41 per share a year ago.
Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
04:17pm, Thursday, 08'th May 2025
RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa
Wall Street Analysts See an 113.25% Upside in Adherex Technologies (FENC): Can the Stock Really Move This High?
10:55am, Wednesday, 30'th Apr 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 113.3% in Adherex Technologies (FENC). While the effectiveness of this highly sought-after metric is questionab
Down -22.15% in 4 Weeks, Here's Why Adherex Technologies (FENC) Looks Ripe for a Turnaround
10:35am, Thursday, 10'th Apr 2025
The heavy selling pressure might have exhausted for Adherex Technologies (FENC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stree
Fennec Pharmaceuticals Inc. (FENC) Q4 2024 Earnings Call Transcript
10:24am, Monday, 10'th Mar 2025
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q4 2024 Earnings Conference Call March 10, 2025 8:30 AM ET Company Participants Robert Andrade - CFO Jeff Hackman - CEO and Board Member Conference Call Part
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates
08:19am, Monday, 10'th Mar 2025
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $0.56. This compares to loss of $0.10 per share a year ago.
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
06:03am, Monday, 10'th Mar 2025
~ Achieved Full-Year PEDMARK ® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK ® Q4 2024 Net Product Sales of $7.9 Million ~
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
04:22pm, Thursday, 06'th Mar 2025
RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Com
Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany
07:00am, Friday, 07'th Feb 2025
~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to
Is the Options Market Predicting a Spike in Adherex Technologies (FENC) Stock?
09:46am, Friday, 24'th Jan 2025
Investors need to pay close attention to Adherex Technologies (FENC) stock based on the movements in the options market lately.
~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and
~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million Shares
